The study indicates patients discount wording that indicates the FDA has not approved supplement claims.
The agreement includes a $1-million payment.
Holding company will now focus on two health networks—FCB Health and McCann Health
NICE greenlights Harvoni for Britain's national formulary, Pacira received a CRL instead of an expanded indication and Novo's latest diabetes outreach focuses on patients instead of drug brands.
Analysts say head-to-head study results could make Kyprolis the lead treatment.
Drugmakers face increasing pressure on pricing from insurers and PBMs.
The breakthrough designation therapy drug was the first for its drug class.
Researchers said 33% of Medicare Part D nursing home patients were receiving the drug for symptoms associated with dementia.
Boston Scientific buys Endo men's health business; Ranbaxy generic Nexium and Valcyte approvals denied by courts; BMS receives priority review for Opdivo lung-cancer indication.
Novartis heart failure drug's trial changed due to Alzheimer's disease concerns; Gilead appears to be stashing profits overseas; BMS releases high cure rate data for its investigational HCV combination.
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.
- Poll shows all ages seek digital health tools
- Survey shows docs overestimate adherence
- Drugmaker shifts sales model to keep pace with formulary decision making
- Oncologist's petition is latest salvo, as drug-pricing issue rises to new prominence
- Global cancer drug market to grow to $111 billion by 2020: report